Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Boston Beer Faces Negative Sentiment Ahead of Q3, UBS Says

Boston Beer Faces Negative Sentiment Ahead of Q3, UBS Says

MT newswireMT newswire2026/10/16 15:58
11:58 AM EDT, 10/16/2026 (MT Newswires) -- Boston Beer (SAM) is still faced with negative sentiment heading into its Q3 results on Oct. 22, UBS said in a note Thursday. "Our conversations would suggest sentiment continues to lean negative as topline trends remain challenged," the note said, pointing to weakness across Twisted Tea and Truly that more than offset strong growth from its Sun Cruise beverage. UBS analysts forecast Q3 EPS of $4.21, slightly below the Visible Alpha consensus of $4.22. The report said its margin progression is encouraging but the company needs to show improvement in underlying volumes to drive sustainable earning growth. "We continue to believe greater visibility on the volume trajectory is needed before becoming more constructive," the note said. UBS kept its neutral rating and a $190 price target. Price: 181.19, Change: +1.99, Percent Change: +1.11
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss